This report also includes revenue forecasts for the 43 leading marketed antibacterial drugs from 2019-2029. For full report, visit: Visiongain.com Direct link: https://www.visiongain.com/report/global-antibacterial-drugs-market-2019-2029/

1. www.visiongain.com/industries/pharma Page 62
Global Antibacterial Drugs Market 2019-2029:
Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, Carbapenems and Others
4. Cephalosporins Market Forecast 2019-2029
Cephalosporin drugs are among the most diverse classes of antibiotics, and are themselves sub-
grouped into first, second, third, fourth, and the recent fifth generation drugs. Each generation has a
broader spectrum of activity than its predecessor. The third-generation drugs, cefotaxime,
ceftizoxime, ceftriaxone and some others can cross the blood-brain barrier (BBB) and may be used
to treat meningitis and encephalitis. Fifth generation cephalosporins are beginning to reach the
market now, with Teflaro and Zeftera the most recent market entrants. The next generation of
cephalosporins are being developed in combination with β-lactamase inhibitors. Cephalosporin’s are
the preferred agents for prophylactic treatment of surgical site infections. Cephalosporins are among
the most commonly prescribed classes of antibiotics worldwide, reportedly leading in emerging
markets and ranking second to penicillins in developed markets. The first cephalosporin was
launched in the mid-1960s. There are now seven cephalosporin products identified in the market
(Table 4.1).
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important
Facts, 2018
Drug Company First Approval
First Patent
Expiry
Administration
Route
Rocephin (ceftriaxone) Roche 1986 2002 IV, IM
Zinnat/Ceftin (cefuroxime) GSK 1987 2003 Oral
Flomox (cefcapene
pivoxil)
Shionogi 1997 2010 Oral
Sulperazon
(cefoperazone/sulbactam)
Pfizer 1982 - IV, IM
Meiact (cefditoren pivoxil)
Vansen Pharma / Meiji
Seika Pharma
1994 2016 Oral
Teflaro / Zinforo
(ceftaroline fosamil)
Forest Labs /
AstraZeneca
2011 2018 IV
Zeftera (ceftobiprole) Basilea Pharmaceutica 2013 2023 IV
4.1 Cephalosporins Market 2018 – No Dominant Brands
In 2018, the cephalosporin submarket was the largest sector of the antibacterial drugs market,
accounting for 27.5% of the global antibacterial drug market at revenue of $11.78bn. The three
highest earing brands are in this class are Pfizer’s Sulperazon, Takeda’s Teflaro and Roche’s
Rocephin. In 2018, these drugs achieved revenues of $0.29bn, $0.53bn and $0.29bn and accounting
for 2.5%, 4.5% and 2.5% of the submarket respectively (Table 4.2 and Figure 4.1).
Source: Visiongain 2019, Drugs.com

2. www.visiongain.com/industries/pharma Page 228
Global Antibacterial Drugs Market 2019-2029:
Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, Carbapenems and Others
Table 11.18 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn),
Annual Growth (%), CAGR (%), 2019-2029
Figure 11.12 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn),
2019-2029
11.8 Japan – Still the Fourth Largest National Market
In terms of antibacterial drug revenues, Japan is the world’s fourth largest market. In 2018, revenues
for antibacterial drugs there totalled $3.54bn. Many leading antibacterial drugs are marketed there
by domestic manufacturers. A number of the world’s leading antibiotics were also developed in that
country, including meropenem (marketed worldwide as Merrem by AstraZeneca and in Japan as
Meropen by Dainippon Sumitomo) and levofloxacin (marketed as Levaquin worldwide by J&J and
as Cravit in Japan by Daiichi Sankyo). As well as these globally available products, a number of
antibacterial drugs are available in the Japanese - or Asian - market only.
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Spain 0.76 0.76 0.76 0.78 0.80 0.81 0.83 0.85 0.87 0.89 0.91 0.93
Annual Growth (%) 0.0% 0.0% 2.6% 2.6% 1.3% 2.5% 2.4% 2.4% 2.3% 2.2% 2.2%
CAGR (2019-2023)
CAGR (2019-2029)
1.6% CAGR (2024-2029) 2.3%
2.0%
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Revenue($bn)
Year
Source: Visiongain 2019
Source: Visiongain 2019. CAGR for period 2019-2023, 2024-2029, and 2019-2029

3. www.visiongain.com/industries/pharma Page 253
Global Antibacterial Drugs Market 2019-2029:
Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, Carbapenems and Others
12.7.3 Key Developments
Table 12.14 Allecra Therapeutics GmbH: Developments
Date Type Description
February, 2018 Designation Allecra Therapeutics announced
that the U.S Food and Drug
Administration (FDA) granted Fast
Track designation for the
company’s lead product candidate
AAI101 when given in fixed dose
combination with the antibiotic
cefepime, a powerful treatment for
serious hospital-acquired
Infections
12.8 Adenium Biotech ApS
12.8.1 Overview
Founded in 2011 and headquartered at Denmark, Adenium Biotech ApS, spun out from Novozymes
A/S in 2011, is a clinical stage biopharmaceutical company which engages in the development and
commercialization of antibiotics for the treatment of gram-negative bacterial infections. The company
specializes in solutions for the treatment of hospital-acquired infections, such as complicated urinary
tract infections and hospital acquired pneumonia caused by multi-resistant gram-negative bacteria.
12.8.2 Pipeline Portfolio
Table 12.15 Adenium Biotech ApS: Pipeline Portfolio
Product Indication Phase
AA139
AA139
AP138
MDR cUTI
MDR G neg Pneumonia
MRSA Implant Infection
Phase I
Phase I
Phase I
Source: Visiongain 2019
Source: Visiongain 2019